News | January 12, 2026
Evotec subsidiary bags Gates Foundation grant to expand global access to biologics
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Heart failure affects an estimated 64.3 million people worldwide
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Subscribe To Our Newsletter & Stay Updated
